Health and Healthcare
Day Trader Alert: Biogen Idec & Another PML Case (BIIB, ELN)
Published:
Last Updated:
Biogen Idec Inc. (NASDAQ: BIIB) just came out with an SEC filing showing that on December 11, 2008, regulatory agencies were notified of a confirmed case of progressive multifocal leukoencephalopathy. In other words, it found another PML case in a multiple sclerosis patient treated with TYSABRI. This is also affecting shares of its partner Elan Corp. plc (NYSE: ELN).
This was in the commercial setting in the European Union as part ofTYGRIS: TYSABRI Global Observational Program in Safety — ROW.Additional notes issued are as follows:
Shares are now trading down 8% pre-market at $43.05, but this is onvery thin trading volume and the spread appears to be very wide. As a reminder, these PML risks have been associated with TYSABRI and the company sees this from time to time now. To see how much this stock bounced off of lows after the dust settles, the 52-week trading range $37.21 to $73.59.
Elan Corp. plc (NYSE: ELN) is its partner, and its shares are down 6% pre-market at $6.74.
Jon C. Ogg
December 15, 2008
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.